Navigation Links
Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes

Scientists at Joslin Diabetes Center have discovered that a surprisingly high percentage of people with type 1 diabetes (insulin-dependent) who have had the disease for 50 years or longer (The Joslin Medalists) may still have residual functioning, insulin-producing islet cells and/or islet cell antibodies. The findings will be presented June 12 at the American Diabetes Association (ADA) 66th Annual Scientific Sessions in Washington, D.C.

"It is surprising that some Medalists still have c-peptide secretion, a sign of insulin production, and some are positive for antibodies to the islets, another sign that some islet function or mass still is present. The significance of these findings is that even after such a prolonged period of diabetes, some patients still have residual islet function," said George L. King, M.D., the study's lead author. Dr. King is Joslin's Research Director, Head of the Section on Vascular Cell Biology, head of Joslin's 50-Year Medalist Study and a Professor of Medicine at Harvard Medical School.

In addition, the researchers found 48 percent of the total participants reported no or very little microvascular complications, such as kidney and eye problems, which demonstrates that long duration of diabetes does not always progress to complications. There also was no significant difference in age, duration, age of onset or long-term glucose control measured by A1C (glycated hemoglobin) levels between those with or without complications.

This talk is one of nearly 80 presentations to be delivered by Joslin scientists at the ADA's Scientific Sessions, Friday, June 9, through Tuesday, June 13. Some 15,000 scientists, physicians and health professionals will attend the conference, to be held at the Washington Convention Center. The talk, "Immune Tolerance and Other Treatment Approaches for Type 1 Diabetes," is scheduled for June 12 at an 8-10 a.m. EST session on Immunology/Transplantation. [Abstract Number 278-OR: "Positivity o f C-peptide, GADA and IA2 antibodies in Type 1 Diabetic Patients with Extreme Duration"]

Since 1970, Joslin Diabetes Center in Boston has awarded medals or certificates to people with type 1 diabetes who have been insulin-dependent continuously for at least 25 years. To date there have been approximately 2,400 50-Year Medals awarded and 17 distinctive 75-Year Medals. The Medalist Study began in April 2005 to identify physiological, clinical, genetic and other factors shared by the Medalists.

The study being presented at the ADA meeting is part of the second phase of the Joslin 50-Year Medalist Study that is assessing these factors in 326 patients with more than 50 years of insulin-dependent diabetes. It evaluated a subset of 125 people with type 1 diabetes for biomarkers of insulin function. Of this group, 12.7 percent had a c-peptide level greater than 0.3 ng/mL, which indicates active islet cells and some residual insulin production. Most of the Medalists have the characteristics associated with type 1 diabetes with or without the presence of c-peptide.

In addition, 23.2 percent of the c-peptide positive participants produced either of two antibodies, GADA and IA2, which attack islet cells. The study also found that 17 percent of participants who were not c-peptide positive produced GADA or IA2 antibodies to the islet cells, another indication that a small amount of islet cells may still be present and/or functioning.

"The findings are phenomenal," said Hillary Keenan, Ph.D., research associate at Joslin and co-investigator on the 50-Year Medalist Study, who will present the findings. "This is the first study to look at the specific biomarkers for islet cell presence in people with a 50-year duration of insulin-dependent diabetes." Other Joslin investigators in the study included Alessandro Doria, M.D., Ph.D., Lloyd Paul Aiello, M.D., Ph.D., Korey Hood, Ph.D., and Jennifer Sun, M.D.

The group also was tested for other cli nical parameters, such as cholesterol, triglycerides, body mass index and daily insulin dose. The data shows no significant difference in clinical parameters for participants with or without c-peptide. For example, the average total cholesterol of the c-peptide positive participants was 146 compared to 162 for the participants who did not produce c-peptide.

"If we could find out the reason for their lack of complications, we could perhaps prevent kidney or eye disease," said Dr. King. The study has been investigating whether other factors, such as lifestyle or longevity genes, play a role in the development of complications, reported Dr. Keenan.

Overall, the study opens new avenues for research and treatment of type 1 diabetes. "The findings suggest that many patients, even after many years of diabetes, may still have some residual islet function. If a way can be found to stimulate islet growth, we could improve their diabetes and reduce insulin usage or better control blood glucose levels. If islets were returned to normal levels, they wouldn't need to take insulin," said Dr. King.

Of the 326 Joslin 50-Year Medalist Study respondents who have completed an extensive health questionnaire, 175 were female and 151 were male, with an average age of 70 years. The average age of diabetes onset was 13 years and average duration of type 1 diabetes 57 years. The data collected so far show that individuals who have survived 50 years or more have a greatly reduced risk of nephropathy and retinopathy.


Source:Joslin Diabetes Center

Related biology news :

1. Big hips, big belly? Its in your genes, Joslin-led study shows
2. UCSD team discovers specialized, rare heart stem cells in newborns
3. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
4. MIT chemist discovers secret behind natures medicines
5. Mayo Clinic collaboration discovers protein amplifies DNA injury signals
6. Expedition discovers marine treasures
7. Team discovers possible universal strategy to combat addiction
8. Nobelist discovers antidepressant protein in mouse brain
9. Contrary to common wisdom, scientist discovers some mammals can smell objects under water
10. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
11. LSU professor discovers new species
Post Your Comments:

(Date:10/8/2015)... Calif. , Oct. 8, 2015 ... of human interface solutions, announced today that it ... of fiscal 2016 on Thursday, October 22, 2015, ... host a corresponding conference call for analysts and ... during which management may discuss forward-looking information.    ...
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/6/2015)... , Oct. 6, 2015  Maverix Biomics, Inc., ... enhancements to its software portfolio with the debut ... for differential expression in eukaryotes. The software is ... a cloud-based genomic analysis solution that leverages proven ... from next-generation sequencing efforts. Garry Nolan,s ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... 2015 PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed ... at near average with 1,308,352 shares being traded. PMCB shares ... hitting a low of $.072 in September, then bouncing back ... Our due diligence will show investors in PharmaCyte Biotech, ... report by using the link below at no cost. ...
(Date:10/13/2015)... , October 13, 2015 " Microbiology ... Forecast 2015 - 2023 " , the global ... is anticipated to reach US$7.59 bn by 2023, expanding at a ... --> " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ...
(Date:10/13/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting company at the Dawson James Small Cap ... Jupiter, Florida on October 15, ... clinical-stage immunotherapy company specializing in the development of innovative ...
(Date:10/13/2015)... Charlotte, NC (PRWEB) , ... October 13, 2015 ... ... high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo ... 450 in the U.S. for the ablation of prostate tissue. Sonablate® is ...
Breaking Biology Technology: